高剂量利妥昔单抗与PLA2R1相关膜性肾病的早期缓解
结果显示NICE组第6个月缓解率更高(64% vs 30%,P=0.02),中位缓解时间更短(3 vs 9个月,P=0.01),且利妥昔单抗血药浓度更高、CD19计数更低、抗PLA2R1抗体水平更低。诊断时表位扩展阴性及第3个月利妥昔单抗水平较高与缓解相关,表位扩展阳性及第6个月抗PLA2R1抗体未完全耗竭与复发相关。
要点
- 高剂量利妥昔单抗(1g×2,间隔2周)较标准剂量(375mg/m2×2,间隔1周)第6个月缓解率更高(64% vs 30%)。
- 诊断时表位扩展阴性者全部获得缓解,且与较低复发相关。
- 第3个月利妥昔单抗水平较高与第6个月缓解相关,第6个月抗PLA2R1抗体未完全耗竭与复发相关。
核心结论
- 高剂量利妥昔单抗方案在耗竭B细胞方面更有效。
- 缺乏表位扩展与膜性肾病缓解相关。
研究设计与样本
- 测量血清利妥昔单抗水平,比较第6个月及治疗修改前的缓解率,分析缓解和复发相关因素。
主要发现
- 中位缓解时间:NICE组3个月(IQR 3-9),GEMRITUX组9个月(IQR 6-12),P=0.01。
- 第3个月利妥昔单抗水平:NICE组3.3 µg/L(IQR 0.0-10.8),GEMRITUX组0.0(IQR 0.0-0.0),P<0.001;CD19计数:NICE组0.0(IQR 0.0-2.0),GEMRITUX组16.5(IQR 2.5-31.0),P<0.001。
- 第6个月抗PLA2R1抗体水平:NICE组0.0(IQR 0.0-8.0),GEMRITUX组8.3(IQR 0.0-73.5),P=0.03。
关键数值与推荐
- 合并人群中,诊断时表位扩展较低者第6个月缓解率13/26(50%),较高者22/29(76%),P=0.05。
- 合并人群中,第6个月缓解者第3个月利妥昔单抗水平2.2 µg/ml(IQR 0.0-10.9),未缓解者0.0 µg/ml(IQR 0.0-0.0),P<0.001。
- 41例达到缓解者中8例复发;复发与诊断时表位扩展阳性(8/8(100%) vs 16/33(48%),P=0.01)及第6个月抗PLA2R1抗体未完全耗竭(4/8(50%) vs 5/33(9%),P=0.05)相关。
临床怎么用
- 高剂量利妥昔单抗方案可能更早达到缓解,但需结合患者表位扩展状态及药物浓度监测个体化选择。
- 诊断时表位扩展阴性者无论采用何种方案均获得缓解,提示可考虑该标志物指导治疗。
- 第6个月抗PLA2R1抗体未完全耗竭者复发风险较高,应加强监测。
局限性
- 研究比较两个独立队列,非随机对照,可能存在混杂偏倚。
- 复发分析基于41例缓解者,事件数较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Different rituximab protocols are used to treat membranous nephropathy. We compared two rituximab protocols in patients with membranous nephropathy. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Twenty-eight participants from the NICE cohort received two infusions of 1-g rituximab at 2-week intervals, whereas 27 participants from the Prospective Randomized Multicentric Open Label Study to Evaluate Rituximab Treatment for Membranous Nephropathy (GEMRITUX) cohort received two infusions of 375 mg/m2 at 1-week interval. We measured serum rituximab levels and compared remission at month 6 and before any treatment modification and analyzed factors associated with remission and relapses. RESULTS: Remissions occurred in 18 (64%) versus eight (30%) from the NICE and GEMRITUX cohort (P=0.02) at month 6, respectively, and in 24 (86%) versus 18 (67%) participants (P=0.12) before treatment modification, respectively. Median time to remission was 3 [interquartile range (IQR), 3-9] and 9 [IQR, 6-12] months for NICE and GEMRITUX cohorts respectively (P=0.01). Participants from the NICE cohort had higher circulating level of rituximab and lower CD19 counts (3.3 µg/L [IQR, 0.0-10.8] versus 0.0 [IQR, 0.0-0.0] P<0.001 and 0.0 [IQR, 0.0-2.0] versus 16.5 [IQR, 2.5-31.0] P<0.001) at month 3, lower level of anti-PLA2R1 antibodies at month 6 (0.0 [IQR, 0.0-8.0] versus 8.3 [IQR, 0.0-73.5] P=0.03). In the combined study population, lower epitope spreading at diagnosis and higher rituximab levels at month 3 were associated with remissions at month 6 (13/26 (50%) versus 22/29 (76%) P=0.05 and 2.2 µg/ml [IQR, 0.0-10.9] versus 0.0 µg/ml [IQR, 0.0-0.0] P<0.001 respectively). All non-spreaders entered into remission whatever the protocol. Eight of the 41 participants who reached remission had relapses. Epitope spreading at diagnosis (8/8 (100%) versus 16/33 (48%) P=0.01) and incomplete depletion of anti-PLA2R1 antibodies at month 6 (4/8 (50%) versus 5/33 (9%) P=0.05) were associated with relapses. CONCLUSIONS: Our work suggests that higher dose rituximab protocol is more effective on depletion of B-cells and lack of epitope spreading is associated with remission of membranous nephropathy.
引用
- Seitz-Polski B, Dahan K, Debiec H, et al. High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy. Clin J Am Soc Nephrol. 2019. PMID: 31340979. doi:10.2215/CJN.11791018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。